Motley Fool Wealth Management LLC Reduces Stock Holdings in West Pharmaceutical Services, Inc. $WST

Motley Fool Wealth Management LLC reduced its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 10.9% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 29,467 shares of the medical instruments supplier’s stock after selling 3,611 shares during the quarter. Motley Fool Wealth Management LLC’s holdings in West Pharmaceutical Services were worth $6,448,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Zions Bancorporation National Association UT purchased a new stake in shares of West Pharmaceutical Services during the 1st quarter valued at about $25,000. Quarry LP purchased a new stake in shares of West Pharmaceutical Services during the 1st quarter valued at about $27,000. First Horizon Advisors Inc. raised its holdings in shares of West Pharmaceutical Services by 85.0% during the 1st quarter. First Horizon Advisors Inc. now owns 185 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 85 shares during the period. CVA Family Office LLC raised its holdings in shares of West Pharmaceutical Services by 573.3% during the 2nd quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock valued at $44,000 after buying an additional 172 shares during the period. Finally, Cromwell Holdings LLC raised its holdings in shares of West Pharmaceutical Services by 587.5% during the 2nd quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier’s stock valued at $48,000 after buying an additional 188 shares during the period. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on WST shares. Zacks Research lowered West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 23rd. Rothschild & Co Redburn started coverage on West Pharmaceutical Services in a research note on Monday, September 15th. They set a “buy” rating and a $311.00 price objective for the company. Rothschild Redb upgraded West Pharmaceutical Services to a “strong-buy” rating in a research note on Monday, September 15th. Deutsche Bank Aktiengesellschaft set a $345.00 price objective on West Pharmaceutical Services and gave the company a “buy” rating in a research note on Friday. Finally, Evercore ISI raised their price objective on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “outperform” rating in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $349.11.

West Pharmaceutical Services Price Performance

Shares of WST opened at $286.82 on Tuesday. The firm has a market cap of $20.63 billion, a price-to-earnings ratio of 42.49, a PEG ratio of 4.40 and a beta of 1.07. The stock has a 50 day moving average of $260.17 and a 200-day moving average of $235.24. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 52 week low of $187.43 and a 52 week high of $348.90.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 EPS for the quarter, topping the consensus estimate of $1.67 by $0.29. The company had revenue of $804.60 million during the quarter, compared to analyst estimates of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The business’s revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. As a group, analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.